RxDoctor Payments Data

Stephen Edwards

Optometrist · Water Valley, MSNPI 1013015585

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,998 of the $3,087 with a category attached, or 64.7%. 12 manufacturers reported payments, led by Coopervision Inc. at 34.9% of the total. 2025 is the largest year on record at $1,444, 6.5 times the $223 reported in 2019.

$3,087in general payments, 2019–2025

Across 32 payments — averaging $96.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$1K
  • Alcon$551
  • Carl Zeiss Meditec USA, Inc.$343
  • Glaukos Corporation$289
  • AbbVie$208
  • Eyepoint US, Inc.$135
  • plus $484 from 6 others

What the payments were for

  • Speaking & faculty fees$1,00032%
  • Food & beverage$1,99865%
  • Entertainment$893%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,087 in reported general payments places this provider in the 85th percentile of 372 optometrist providers in Mississippi.

See all optometrist providers in Mississippi

Medicare billing

Part B allowed, 2024
$99,202
Medicare patients
426
Services billed
1,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost109$38,338
CombiganBrimonidine Tartrate/Timolol26$8,991
VyzultaLatanoprostene Bunod24$8,246
Alphagan PBrimonidine Tartrate17$4,954
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat140$2,454
Prednisolone Acetate61$2,216
Latanoprost315$2,177
Brimonidine Tartrate35$644
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha48$512
Timolol Maleate46$363
Dorzolamide Hcl24$330
ErythromycinErythromycin Base20$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$208$52,283152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 372 optometrist providers in Mississippi.

Other optometrist in Water Valley

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →